Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Develops Blood-Based RNAi Monitoring Approach

Premium

Alnylam Pharmaceuticals this week announced that it has developed a new method for monitoring RNAi activity in blood samples.

According to the company, the approach allows for the “quantitative measurement of tissue-specific mRNA silencing from biological fluids including blood and cerebrospinal fluid.” Alnylam said it expects to “enable” the use of the technology by academics and out-license it for industry applications.

A license has already been granted to Isis Pharmaceuticals.

The method “enables routine and frequent measurement of tissue-specific target gene silencing, without the need for invasive tissue biopsies,” Alnylam Vice President of Research Rachel Meyers said in a statement.